Newsoara HYK Biopharmaceuticals Co., Ltd.
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | No discrete molecular targetOncolytic virus | Non-Small Cell Lung CancerOvarian Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Olvimulogene nanivacirepvecPhase 3Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer …
Est. primary completion 2026-12 · NCT05281471 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
Olvimulogene nanivacirepvecPhase 2Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma …
Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.